Company profile: Delphinus Medical
1.1 - Company Overview
Company description
- Provider of breast cancer screening solutions for hospitals and imaging clinics, developing, commercializing, and servicing the SoftVue 3D Whole Breast Ultrasound Tomography, a 3D whole breast ultrasound system for dense breast screening that increases cancer detection by 20% when used alongside mammography.
Products and services
- SoftVue™ 3D Whole Breast Ultrasound Tomography: A dense-breast-focused ultrasound system that images the entire breast volume and increases cancer detection by 20% when used alongside mammography
- Product Development for Breast Screening Systems: Clinic-focused R&D that architects 3D whole-breast ultrasound tomography products for hospitals and imaging clinics, targeting dense breasts and adjunct use with mammography
- Commercialization and Servicing of Breast Screening Products: Hospital-focused programs that supply and service breast cancer screening systems to hospitals and imaging clinics, including SoftVue used alongside mammography for dense breast screening
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Delphinus Medical
Halozyme
HQ: United States
Website
- Description: Provider of extracellular matrix-targeting products and drug delivery technologies, including ENHANZE to enable subcutaneous delivery and reduce administration time vs hours-long IV infusions; HYLENEX recombinant hyaluronidase to aid dispersion and absorption of injected drugs/fluids; XYOSTED testosterone enanthate for replacement therapy; and auto-injector platforms for subcutaneous/intramuscular use, with a partner pipeline in five approved therapeutics.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Halozyme company profile →
Exact Sciences
HQ: United States
Website
- Description: Provider of cancer diagnostics, including Cologuard, a non-invasive at-home stool-based colorectal cancer screening test for individuals 45+, Riskguard hereditary cancer testing, Oncotype DX Breast Recurrence Score to assess recurrence and guide treatment for ER+/HER2- breast cancer, OncoExTra genomic profiling for therapy selection in advanced/metastatic cancer, and under-development Breast Radiation Score and colorectal cancer blood test.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Exact Sciences company profile →
Ambit Biosciences
HQ: United States
Website
- Description: Provider of small molecule kinase inhibitor discovery and development for cancer, autoimmune, and inflammatory diseases, including quizartinib (AC220), a potent, selective FLT3 inhibitor for AML, AC410 (JAK2 inhibitor), and AC708 (CSF1R inhibitor), supported by the KinomeScan platform for screening kinase inhibitors.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ambit Biosciences company profile →
Angle
HQ: United Kingdom
Website
- Description: Provider of liquid biopsy cancer diagnostic products for the capture and harvest of circulating tumor cells.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Angle company profile →
EMulate Therapeutics
HQ: United States
Website
- Description: Provider of clinical-stage therapeutic devices using proprietary ultra-low radio frequency energy (ulRFE) to elicit therapeutic biological effects. Programs include clinical testing in brain cancer and preclinical work in pain and mental health, advanced by subsidiaries: Cellsana (oncology; Phase III prep for glioblastoma/diffuse midline glioma), Mensana (mental health; Phase I prep), and Indolor (pain; Phase I prep).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full EMulate Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Delphinus Medical
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Delphinus Medical
2.2 - Growth funds investing in similar companies to Delphinus Medical
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Delphinus Medical
4.2 - Public trading comparable groups for Delphinus Medical
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →